HRP20161348T1 - Deuterirani 1-piperazino-3-fenil indani za liječenje shizofrenije - Google Patents

Deuterirani 1-piperazino-3-fenil indani za liječenje shizofrenije Download PDF

Info

Publication number
HRP20161348T1
HRP20161348T1 HRP20161348TT HRP20161348T HRP20161348T1 HR P20161348 T1 HRP20161348 T1 HR P20161348T1 HR P20161348T T HRP20161348T T HR P20161348TT HR P20161348 T HRP20161348 T HR P20161348T HR P20161348 T1 HRP20161348 T1 HR P20161348T1
Authority
HR
Croatia
Prior art keywords
substance
deuterium
image
atom
treatment
Prior art date
Application number
HRP20161348TT
Other languages
English (en)
Inventor
Morten Jorgensen
Peter Hongaard Andersen
Klaus Gjervig Jensen
Mette Graulund Hvenegaard
Lassina Badolo
Mikkel Fog Jacobsen
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of HRP20161348T1 publication Critical patent/HRP20161348T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Claims (31)

1. Tvar formule Y [image] pri čemu R1-R10 su nezavisno vodik ili deuterij, pri čemu su R6-R10 svaki deuterij, pri čemu najmanje jedan od R1-R10 sadrži najmanje oko 50% deuterija, ili njena farmaceutski prihvatljiva sol dobivena adicijom kiseline.
2. Tvar iz patentnog zahtjeva 1, pri čemu je svaki od R3-R5 vodik.
3. Tvar iz patentnog zahtjeva 1, pri čemu je svaki od R3-R5 deuterij.
4. Tvar iz patentnog zahtjeva 2, pri čemu je tvar [image]
5. Tvar iz patentnog zahtjeva 2, pri čemu je tvar [image]
6. Tvar iz patentnog zahtjeva 3, pri čemu je tvar [image]
7. Tvar iz patentnog zahtjeva 3, pri čemu je tvar [image]
8. Tvar iz patentnog zahtjeva 1, pri čemu je svaki od R1 i R2deuterij.
9. Tvar iz patentnog zahtjeva 8, pri čemu je svaki od R3-R5 deuterij.
10. Tvar iz patentnog zahtjeva 8, pri čemu je svaki od R3-R5 vodik.
11. Tvar iz bilo kojeg od patentnih zahtjeva 1-10, pri čemu najmanje oko 85% tvari ima atom deuterija na svakoj poziciji predviđenoj za deuterij, a svaki je atom koji nije predodređen za deuterij prisutan kao svoj prirodno zastupljeni oblik izotopa.
12. Tvar iz bilo kojeg od patentnih zahtjeva 1-11, pri čemu najmanje oko 90% tvari ima atom deuterija na svakoj poziciji predviđenoj za deuterij, a svaki je atom koji nije predodređen za deuterij prisutan kao svoj prirodno zastupljeni oblik izotopa.
13. Tvar iz patentnog zahtjeva 1, pri čemu je tvar hidrogen tartaratna sol tvari [image]
14. Tvar iz patentnog zahtjeva 13, pri čemu tvar postoji u polimorfnom obliku i ima XRPD uzorak difrakcije kako je prikazano na Slici 18.
15. Tvar iz patentnog zahtjeva 13, pri čemu najmanje oko 85% tvari ima atom deuterija na svakoj poziciji predviđenoj za deuterij, a svaki je atom koji nije predodređen za deuterij prisutan kao svoj prirodno zastupljeni oblik izotopa.
16. Farmaceutski sastav obuhvaća tvar iz bilo kojeg od patentnih zahtjeva 1 do 15 i jedan ili više farmaceutski prihvatljivih nosača, diluenata, ili ekscipijenasa.
17. Farmaceutski sastav iz patentnog zahtjeva 16, pri čemu je tvar hidrogen tartaratna sol tvari [image]
18. Tvar iz patentnih zahtjeva 16 ili 17, pri čemu nosač sadrži hidroksipropil-β-ciklodekstrin u vodi i pri čemu najmanje oko 85% tvari ima atom deuterija na svakoj poziciji predviđenoj za deuterij, a svaki je atom koji nije predodređen za deuterij prisutan kao svoj prirodno zastupljeni oblik izotopa.
19. Uporaba tvari iz bilo kojeg od patentnih zahtjeva 1-15, ili sastava iz bilo kojeg od patentnih zahtjeva 16-18 za proizvodnju lijeka za liječenje psihoza, drugih bolesti koje uključuju psihotične simptome, psihotičke poremećaje ili bolesti koje se manifestiraju psihotičnim simptomima.
20. Uporaba u skladu s patentnim zahtjevom 19, pri čemu su psihoze ili bolesti koje uključuju psihotične simptome shizofrenija, shizofrenoformni poremećaj, shizoafektivni poremećaj, diluzijski poremećaj, kratkotrajni psihotički poremećaj, grupni psihotički poremećaj, bipolarni poremećaj, ili manija u bipolarnom poremećaju.
21. Uporaba u skladu s bilo kojim od patentnih zahtjeva 19-20, nadalje obuhvaća tvar odabranu iz grupe koja sadrži sertindol, olanzapin, risperidon, kvetiapin, aripiprazol, haloperidol, klozapin, ziprasidon i osanetant.
22. Uporaba u skladu s bilo kojim od patentnih zahtjeva 19-20, pri čemu je psihoza ili bolest koja uključuje psihotične simptome shizofrenija.
23. Uporaba u skladu s bilo kojim od patentnih zahtjeva 19-20, pri čemu je psihoza ili bolest koja uključuje psihotične simptome shizofrenija, pri čemu farmaceutski sastav sadrži učinkovitu količinu hidrogen tartaratne soli tvari [image] i hidroksipropil-β-ciklodekstrin u vodi i pri čemu najmanje oko 85% tvari (IV) ima atom deuterija na svakoj poziciji predviđenoj za deuterij, a svaki je atom koji nije predodređen za deuterij prisutan kao svoj prirodno zastupljeni oblik izotopa.
24. Tvar formule [image]
25. Postupak za pripravu tvari [image] obuhvaća tretiranje tvari (XIV) sa [(S)-BINAP]Rh(I)BF4. [image]
26. Postupak iz patentnog zahtjeva 25, pri čemu se [(S)-BINAP]Rh(I)BF4 koristi u katalitičkoj količini.
27. Postupak za pripravu tvari (XIV) obuhvaća a) tretiranje [image] s bis(pinakolato)diboronom, i b) tretiranje s 2-bromo-5-klorobenzaldehidom.
28. Postupak iz patentnog zahtjeva 27, pri čemu tretiranje tvari [image] s bis(pinakolato)diboronom nadalje uključuje dodavanje Pd(II).
29. Postupak iz patentnog zahtjeva 28, pri čemu tretiranje s 2-bromo-5-klorobenzaldehidom nadalje uključuje dodavanje Pd(0).
30. Postupak priprave tvari (1R, 3S)-(IV) tartarata obuhvaća tretiranje racemičnog trans-1-(6-kloro-3-fenil(d5)-indan-1-il)-1(d3),2,2-trimetil-piperazina s L-(+)-vinskom kiselinom.
31. Postupak iz patentnog zahtjeva 30, pri čemu se racemični trans-1-(6-kloro-3-fenil(d5)-indan-1-il)-1(d3),2,2-trimetil-piperazin stvara iz njegove odgovarajuće sukcinatne soli.
HRP20161348TT 2011-06-20 2016-10-17 Deuterirani 1-piperazino-3-fenil indani za liječenje shizofrenije HRP20161348T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161498651P 2011-06-20 2011-06-20
US201161537103P 2011-09-21 2011-09-21
PCT/IB2012/001386 WO2012176066A1 (en) 2011-06-20 2012-06-19 Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
EP12748046.5A EP2720989B1 (en) 2011-06-20 2012-06-19 Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia

Publications (1)

Publication Number Publication Date
HRP20161348T1 true HRP20161348T1 (hr) 2016-12-02

Family

ID=46682855

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20161348TT HRP20161348T1 (hr) 2011-06-20 2016-10-17 Deuterirani 1-piperazino-3-fenil indani za liječenje shizofrenije
HRP20190593TT HRP20190593T1 (hr) 2011-06-20 2019-03-27 Deuterirani 1-piperazino-3-fenil indani za liječenje shizofrenije

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20190593TT HRP20190593T1 (hr) 2011-06-20 2019-03-27 Deuterirani 1-piperazino-3-fenil indani za liječenje shizofrenije

Country Status (40)

Country Link
US (8) US8575174B2 (hr)
EP (4) EP3135656B1 (hr)
JP (1) JP5668177B2 (hr)
KR (2) KR101939546B1 (hr)
CN (1) CN103649019B (hr)
AP (1) AP3310A (hr)
AR (1) AR086987A1 (hr)
AU (1) AU2012273657B2 (hr)
BR (1) BR112013031702B1 (hr)
CA (1) CA2837820C (hr)
CL (1) CL2013003646A1 (hr)
CO (1) CO6821965A2 (hr)
CR (1) CR20130654A (hr)
CY (2) CY1118158T1 (hr)
DK (2) DK2720989T3 (hr)
DO (1) DOP2013000305A (hr)
EA (1) EA024651B1 (hr)
EC (1) ECSP14013155A (hr)
ES (3) ES2719145T3 (hr)
GE (1) GEP201706655B (hr)
GT (1) GT201300304A (hr)
HK (1) HK1197228A1 (hr)
HR (2) HRP20161348T1 (hr)
HU (2) HUE044043T2 (hr)
IL (1) IL229640B (hr)
JO (1) JO3128B1 (hr)
LT (2) LT3135656T (hr)
MA (1) MA35268B1 (hr)
MD (1) MD4538C1 (hr)
ME (2) ME03375B (hr)
MX (1) MX339552B (hr)
MY (1) MY196998A (hr)
PE (2) PE20150928A1 (hr)
PL (2) PL2720989T3 (hr)
PT (2) PT2720989T (hr)
RS (2) RS55304B1 (hr)
SI (2) SI2720989T1 (hr)
SM (1) SMT201600383B (hr)
TW (3) TWI614234B (hr)
WO (1) WO2012176066A1 (hr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE044043T2 (hu) 2011-06-20 2019-09-30 H Lundbeck As Deuterizált 1-piperazino-3-fenil-indánok skizofrénia kezelésére
AR094054A1 (es) * 2012-12-19 2015-07-08 H Lundbeck As 6-cloro-3-(fenil-d₅)-inden-1-ona y uso de la misma
WO2019049918A1 (en) 2017-09-07 2019-03-14 Otsuka Pharmaceutical Co., Ltd. INDUSTRIAL PROCESS FOR MONOALKYLATION OF PIPERIDINE NITROGEN IN PIPERIDINE DERIVATIVES WITH DEUTERATED ALKYL
WO2020089147A1 (en) 2018-10-29 2020-05-07 H. Lundbeck A/S Amorphous compounds of formula (i) and amorphous compounds of formula (i) salts
CN113056457A (zh) 2018-12-03 2021-06-29 H.隆德贝克有限公司 4-((1R,3S)-6-氯-3-苯基-2,3-二氢-1H-茚-1-基)-1,2,2-三甲基哌嗪和4-((1R,3S)-6-氯-3-(苯基-d5)-2,3-二氢-1H-茚-1-基)-2,2-二甲基-1-(甲基-d3)哌嗪的前药
US20220106272A1 (en) * 2018-12-21 2022-04-07 Terran Biosciences, Inc. Deuterated Forms And Derivatives Of Volinanserin
CA3132953A1 (en) 2019-03-13 2020-09-17 Otsuka Pharmaceutical Co., Ltd. Method for introducing deuterated lower alkyl into amine moiety of compound containing secondary amine

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE50867B1 (en) 1980-02-29 1986-08-06 Kefalas As Indane derivatives
GB8427125D0 (en) 1984-10-26 1984-12-05 Lundbeck & Co As H Organic compounds
DK286990D0 (da) 1990-12-04 1990-12-04 Lundbeck & Co As H Indanderivater
DK55192D0 (da) 1992-04-28 1992-04-28 Lundbeck & Co As H 1-piperazino-1,2-dihydroindenderivater
CA2186371A1 (en) 1994-03-25 1995-10-05 Robert T. Foster Enhancement of the efficacy of dihydropyridines by deuteration
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
EP1658277B1 (en) 2003-08-18 2012-04-04 H. Lundbeck A/S Succinate and malonate salt of trans-4-(ir,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament
CN101935305B (zh) * 2003-08-18 2013-04-10 H.隆德贝克有限公司 反式-4-((1r,3s)-6-氯-3-苯基茚满-1-基)-1,2,2-三甲基哌嗪及其盐的制备方法及所用中间体
TWI453198B (zh) 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
WO2006086985A1 (en) 2005-02-16 2006-08-24 H. Lundbeck A/S Tartrate and malate salts of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
TWI376373B (en) * 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
US7863274B2 (en) 2005-07-29 2011-01-04 Concert Pharmaceuticals Inc. Deuterium enriched analogues of tadalafil as PDE5 inhibitors
KR101380190B1 (ko) 2005-07-29 2014-04-11 콘서트 파마슈티컬즈, 인크. 벤조 〔ｄ〕〔１,３〕―디옥솔 유도체
JP5302005B2 (ja) 2005-12-01 2013-10-02 オースペックス・ファーマシューティカルズ・インコーポレイテッド セロトニン作動性および／またはノルエピネフリン作動性の活性を有する置換フェネチルアミン
JP4986462B2 (ja) 2006-01-27 2012-07-25 シャープ株式会社 太陽電池ストリングおよびその製造方法、ならびに、その太陽電池ストリングを用いる太陽電池モジュール
TW200819426A (en) 2006-08-31 2008-05-01 Lundbeck & Co As H Novel indane compounds
US8198305B2 (en) 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
US7528131B2 (en) 2007-04-19 2009-05-05 Concert Pharmaceuticals Inc. Substituted morpholinyl compounds
CN101711237B (zh) 2007-06-12 2013-08-07 康塞特制药公司 氮杂肽衍生物
US20090062303A1 (en) 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched ziprasidone
US20090306092A1 (en) 2008-05-07 2009-12-10 H. Lundbeck A/S Method for treating cognitive deficits
NZ590897A (en) 2008-10-03 2012-07-27 Lundbeck & Co As H ORAL FORMULATION COMPRISING (4-((1R,3S)-6-chloro-3-phenylindan-l-yl)-1,2,2-trimethylpiperazine)
WO2010062656A2 (en) 2008-10-28 2010-06-03 Concert Pharmaceuticals Inc. Deuterated 2-propylpentanoic acid compounds
US8263601B2 (en) 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
US8658236B2 (en) * 2009-08-21 2014-02-25 Deuteria Beverages, Llc Alcoholic compositions having a lowered risk of acetaldehydemia
CN102020522A (zh) * 2009-09-21 2011-04-20 陈松源 氘代药物的制备方法和应用
US8278460B2 (en) 2009-10-15 2012-10-02 Concert Pharmaceuticals, Inc. Substituted benzimidazoles
WO2011059080A1 (ja) * 2009-11-16 2011-05-19 第一三共株式会社 同位体置換されたジアミン誘導体
HUE044043T2 (hu) 2011-06-20 2019-09-30 H Lundbeck As Deuterizált 1-piperazino-3-fenil-indánok skizofrénia kezelésére

Also Published As

Publication number Publication date
ES2939477T3 (es) 2023-04-24
TW201311248A (zh) 2013-03-16
CL2013003646A1 (es) 2014-07-04
KR20140041567A (ko) 2014-04-04
US10501427B2 (en) 2019-12-10
HUE030883T2 (en) 2017-06-28
MD4538B1 (ro) 2017-12-31
MX2013014849A (es) 2014-03-31
SI3135656T1 (sl) 2019-05-31
AP2013007338A0 (en) 2013-12-31
PE20150928A1 (es) 2015-06-26
ME03375B (me) 2020-01-20
RS58546B1 (sr) 2019-05-31
TW201722895A (zh) 2017-07-01
US20170158650A1 (en) 2017-06-08
ECSP14013155A (es) 2014-02-28
EP3508468B1 (en) 2023-01-18
LT3135656T (lt) 2019-04-25
SI2720989T1 (sl) 2016-11-30
EP2720989A1 (en) 2014-04-23
EA024651B1 (ru) 2016-10-31
EP3135656A1 (en) 2017-03-01
PT2720989T (pt) 2016-11-07
ES2601213T3 (es) 2017-02-14
US9012453B2 (en) 2015-04-21
MA35268B1 (fr) 2014-07-03
NZ618222A (en) 2015-03-27
US20150307458A1 (en) 2015-10-29
US20130281436A1 (en) 2013-10-24
DOP2013000305A (es) 2014-02-28
CY1121514T1 (el) 2020-05-29
WO2012176066A1 (en) 2012-12-27
AU2012273657A1 (en) 2013-12-12
PL2720989T3 (pl) 2017-05-31
HUE044043T2 (hu) 2019-09-30
GT201300304A (es) 2015-01-16
GEP201706655B (en) 2017-04-25
BR112013031702B1 (pt) 2021-11-03
PE20141113A1 (es) 2014-09-25
PT3135656T (pt) 2019-05-03
JP5668177B2 (ja) 2015-02-12
US20200131143A1 (en) 2020-04-30
EA201490045A1 (ru) 2014-07-30
CA2837820C (en) 2019-02-19
MY196998A (en) 2023-05-17
LT2720989T (lt) 2016-11-25
CN103649019B (zh) 2015-09-16
MD20140004A2 (en) 2014-05-31
TWI627956B (zh) 2018-07-01
BR112013031702A2 (pt) 2016-12-13
CA2837820A1 (en) 2012-12-27
IL229640B (en) 2018-02-28
US11059798B2 (en) 2021-07-13
EP3135656B1 (en) 2019-02-27
HK1197228A1 (zh) 2015-01-09
US20220119362A1 (en) 2022-04-21
TW201902481A (zh) 2019-01-16
US9617231B2 (en) 2017-04-11
KR101939546B1 (ko) 2019-01-16
SMT201600383B (it) 2017-01-10
JP2014520140A (ja) 2014-08-21
EP4215512A1 (en) 2023-07-26
CN103649019A (zh) 2014-03-19
JO3128B1 (ar) 2017-09-20
IL229640A0 (en) 2014-01-30
KR20180075717A (ko) 2018-07-04
HRP20190593T1 (hr) 2019-05-17
US20190031631A1 (en) 2019-01-31
US20160068497A1 (en) 2016-03-10
CY1118158T1 (el) 2017-06-28
KR101879474B1 (ko) 2018-07-17
MX339552B (es) 2016-05-31
AR086987A1 (es) 2014-02-05
US9216961B2 (en) 2015-12-22
TWI614234B (zh) 2018-02-11
US20120322811A1 (en) 2012-12-20
ME02513B (me) 2017-02-20
MD4538C1 (ro) 2018-07-31
TWI659741B (zh) 2019-05-21
EP2720989B1 (en) 2016-08-10
CO6821965A2 (es) 2013-12-31
RS55304B1 (sr) 2017-03-31
EP3508468A1 (en) 2019-07-10
US8575174B2 (en) 2013-11-05
DK2720989T3 (en) 2016-11-28
AP3310A (en) 2015-06-30
ES2719145T3 (es) 2019-07-08
PL3135656T3 (pl) 2019-07-31
AU2012273657B2 (en) 2016-07-21
US10118907B2 (en) 2018-11-06
CR20130654A (es) 2014-03-24
DK3135656T3 (en) 2019-04-23

Similar Documents

Publication Publication Date Title
HRP20161348T1 (hr) Deuterirani 1-piperazino-3-fenil indani za liječenje shizofrenije
ECSP13012892A (es) IMIDAZO[5,1-f][1,2,4]TRIAZINAS PARA EL TRATAMIENTO DE TRASTORNOS NEUROLÓGICOS
JP2014520140A5 (hr)
CN101421228B (zh) 手性酰胺和胺的制备
BR112014018959A8 (pt) Compostos, composições farmacêuticas, utilizações de um composto e métodos para o tratamento do câncer
HRP20110206T1 (hr) Derivati 3-(heteroaril-oksi)-2-alkil-1-aza-bicikloalkila kao alfa.7-nachr liganda za liječenje cns bolesti
MA35903B1 (fr) Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
RU2014101482A (ru) Способ применения 4-((1r,3s)-6-хлор-3-фенилиндан-1-ил)-1,2,2-триметилпиперазина и его солей в лечении шизофрении
HRP20141222T1 (hr) Novi derivati fenilimidazola kao inhibitori enzima pde10a
BR112014010263A2 (pt) método de preparação do acetato de ulipristal e intermediário deste
HRP20140336T1 (hr) Inhibitori glicin transportera-1
CA3025586A1 (en) Pde9 inhibitors for treatment of peripheral diseases
NZ600416A (en) 2-arylimidazole derivatives as pde10a enzyme inhibitors
UY34239A (es) Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento
JP2013542963A5 (hr)
NZ628969A (en) Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
CN102936246A (zh) 丁苯那嗪的合成方法
JP2012519182A5 (hr)
BRPI0407901A (pt) derivados de diarilcicloalquila, processos para preparação dos mesmos e uso dos mesmos como medicamentos
WO2013166276A4 (en) Triazolopyridazine compounds, use as inhibitors of the kinase lrrk2, and methods for preparation thereof
HRP20130234T1 (hr) Derivat dibenzotiazepina i njegova uporaba
CN104774174A (zh) 一种不对称合成s-卡比沙明的方法
MX2009004615A (es) Derivados de eter como moduladores duales de los receptores de 5-hidroxitriptamina a (5-ht2a) y dopamina (d3).
HRP20161167T1 (hr) Spoj akrilamida kao ligandi histaminskog h3 receptora
CN102603592B (zh) (r)-1-苄基-3-氨基吡咯烷和(s)-1-苄基-3-氨基吡咯烷的制备方法